Reply  by Terranova, Giuseppina & Picano, Eugenio
a
r
m
o
o
I
d
a
i
a
I
m
o
m
l
B
d
(
d
s
d
l
f
l
d
m
s
a
c
I
a
(
p
C
u
q
I
p
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 1 , 2 0 1 2
N O V E M B E R 2 0 1 2 : 1 1 8 1 – 5
Letters to the Editor 1185R E F E R E N C E S
1. Terranova G, Ferro M, Carpeggiani C, et al. Low quality and lack of
clarity of current informed consent forms in cardiology: how to improve
them. J Am Coll Cardiol Img 2012;5:649–55.
2. Gould KL, Pan T, Loghin C, Johnson NP, Guha A, Sdringola S.
Frequent diagnostic errors in cardiac PET/CT due to misregistration of
CT attenuation and emission PET images: a definitive analysis of causes,
consequences, and corrections. J Nucl Med 2007;48:1112–21.
3. Gould KL, Pan T, Loghin C, Johnson NP, Sdringola S. Reducing
radiation dose in rest-stress cardiac PET/CT by single poststress cine CT
for attenuation correction: quantitative validation. J Nucl Med 2008;49:
738–45.
4. Johnson NP, Gould KL. Physiological basis for angina and ST-segment
change PET-verified thresholds of quantitative stress myocardial perfu-
sion and coronary flow reserve. J Am Coll Cardiol Img 2011;4:990–8.
REPLY
We thank Drs. Johnson and Gould for their interest in our paper
(1). The “factually incorrect” doses reported in Figure 3 are indeed
correct. Positron emission tomography (PET) scans are usually
coupled with angiogram computed tomography (CT) and lead
precisely to a cumulative (CT angiogram  PET scan) dose of
approximately 20 mSv (1,000 chest x-rays) (2). PET scan alone
(without CT) totals 2 mSv with 13-ammonia, and 3 mSv with
82-rubidium. Obviously, reported doses are only reference doses,
and lower doses can be achieved with state-of-the-art CT technol-
ogy. On the other hand, for each test (from CT to single-photon
emission computed tomography [SPECT] to coronary angiogra-
phy), substantially (up to 5-fold) higher doses can be recorded in
the real world—especially when no systematic dose audit is imple-
mented in the imaging laboratory (3).
We agree that a major advantage of PET myocardial perfusion
imaging is the lower radiation dose when compared with SPECT
(2 mSv vs. 8 to 10 mSv). Obviously, this advantage may apply
mainly in cost-insensitive settings in which there is no technology
or expertise for zero-dose cardiac testing with magnetic resonance
imaging or stress echocardiography—which provide similar diag-
nostic and prognostic results at much lower cost using radiation-
free techniques (4). Only an explicit, systematic discussion of costs
and risks would facilitate the identification of appropriate, sustain-
able medical imaging strategies (5), avoiding the use of high-cost,
high-risk techniques instead of low-cost, low-risk methods with
comparable benefit.
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Intraplaque Hemorrhage,
RBC-Derived Cholesterol,
and Plaque Progression
Time to Move From Conjecture to Evidence?
The interesting study by Sun et al. (1) in a recent issue of iJACC
dds important new insights into the role of intraplaque hemor-
hage (IPH) in the natural history of carotid atherosclerosis. Serial
agnetic resonance imaging (MRI) over an extended period of
bservation demonstrated that plaque growth after the occurrence
f IPH was on average higher compared with the period before
PH (1). Notably, however, the rate of individual plaque growth
iffered substantially after the occurrence of IPH; some plaques
ctually showed regression despite evidence of new IPH, as shown
n Figure 4 of Sun et al. (1). Thus, this study strongly links IPH to
ccelerated atherosclerosis, but it also raises a key issue: detection of
PH alone may be a suboptimal predictor of the exact rate and
agnitude of subsequent plaque growth. Therefore, identification
f other factors that modulate the proatherogenic effect of IPH
ight enhance the potential of MRI to accurately predict which
esions with IPH will exhibit most pronounced and rapid growth.
ased on the pathobiological sequelae of IPH (2), we suggest that
ifferences in the cholesterol contents of erythrocyte membranes
CEM) are very likely to account, at least in part, for the observed
ifferential plaque growth after IPH (1).
The driving mechanisms of plaque progression and the main
ource of cholesterol that is accumulated in the developing plaque
iffer fundamentally in lesions without versus those with IPH. In
esions without IPH, cholesterol in the plaque is derived mainly
rom circulating blood lipoproteins; hence, higher blood cholesterol
evels amplify the proatherogenic stimulus of adverse local hemo-
ynamics, which is a major driving force of focal plaque develop-
ent in this setting (3). In contrast, in lesions with IPH extrava-
ated erythrocytes contain abundant free cholesterol that is
bsorbed into the necrotic core and is conjectured to contribute
entrally to plaque enlargement (2). Accordingly, in lesions with
PH, it seems highly plausible that increasing levels of CEM might
mplify the proatherogenic stimulus of IPH per se.
Of clinical importance, the CEM can be measured in the clinic
4,5) and is positively related to coronary plaque burden (4) and
laque instability (5). We hereby propose that the combination of
EM measurement with serial MRI may substantiate our current
nderstanding of the role of IPH in plaque biology and, conse-
uently, may enhance risk-stratification of patients with evidence of
PH. First, a finding of greatest plaque progression after IPH in
atients with higher compared with those with lower CEM levels
ould lend definitive mechanistic support to the long-standing
